Company Filing History:
1 out of 560 
1 out of 8 Years Active: 2025
Title: Innovations of Inventor Xinlei Chen
Introduction
Xinlei Chen is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of immunology, particularly in the development of targeted therapies for cancer. His work focuses on innovative approaches to combat DLL3-associated cancers.
Latest Patents
Xinlei Chen holds a patent for "DLL3-targeting antibodies and uses thereof." This patent relates to immunoglobulin-related compositions, such as antibodies or antigen-binding fragments that can bind to delta-like protein 3 (DLL3). The antibodies developed through this technology are useful in methods for detecting and treating DLL3-associated cancers in subjects in need.
Career Highlights
Throughout his career, Xinlei Chen has worked with esteemed institutions, including Memorial Sloan Kettering Cancer Center and the Tri-Institutional Therapeutics Discovery Institute. His experience in these organizations has allowed him to contribute to groundbreaking research and advancements in cancer treatment.
Collaborations
Xinlei Chen has collaborated with notable colleagues, including John Poirier and Charles Rudin. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer therapies.
Conclusion
Xinlei Chen's work in developing DLL3-targeting antibodies represents a significant advancement in cancer treatment. His contributions to immunology and collaboration with leading institutions highlight his commitment to improving patient outcomes.